AMR Benchmark homepage
The superbugs can be stopped - if we put good ideas into action
The AMR Benchmark: First report on pharma's response to AMR
The 2018 Antimicrobial Resistance Benchmark compares how pharmaceutical companies are bringing AMR under control. It covers R&D, responsible manufacturing, appropriate access and stewardship.
28 antibiotics for priority pathogens - two stand out
The pipelines captured in the Benchmark have 175 antimicrobial medicines targeting pathogens seen by WHO and CDC as the biggest AMR threats, including 28 antibiotic candidates in late stages of clinical development.
Nine companies are tracking drug resistance
Curbing AMR depends on knowing where pathogens are developing resistance. Nine companies are running or supporting 19 AMR surveillance programmes across 147 countries.
News related to the Antimicrobial Resistance Benchmark
Methodology for the 2020 Antimicrobial Resistance Benchmark
What leaders say
"The AMR Benchmark brings much-needed clarity to how pharmaceutical companies approach AMR, which means investors can assess how pharmaceutical companies manage opportunities and risks created by drug-resistant infections. Such scrutiny by investors will spur pharma executives to greater activity."
Former Chair of the UK Review on AMR
This independent Antimicrobial Resistance Benchmark is a huge step forward and shines a light on the pharmaceutical industry’s progress in tackling drug-resistant infections. It can help pave the way for a transparent learning culture where best practice is shared, progress celebrated, and gaps where further work is needed are identified”
Dame Sally Davies
Professor Dame Sally Davies, Chief Medical Officer and co-convener of the UN Inter-Agency Co-ordination Group on AMR
"We desperately need new antibiotics, but we can’t let the new ones go to waste. The AMR Benchmark is an important tool to spur progress on innovation, appropriate use, and clean manufacturing, providing an independent assessment following the Davos Declaration and the Industry Roadmap released in 2016.
Professor of Law at Boston University and Executive Director of CARB-X
"There are real solutions for slowing AMR. By identifying which pharmaceutical companies are taking action, we can help good ideas to spread."
Jayasree K. Iyer
Executive Director Access to Medicine Foundation
View our detailed overview of each company’s performance